Bruce N. Jacobs

Companies

• Kymera TherapeuticsChief financial officer Aug 20, 2020 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• KTKymera Therapeutics KYMR244,883 shares²$26.5M at $108.02Jun 30, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Jun 30, 2026Sold 3,200 shares at $117.70 of Kymera Therapeutics²
• Jun 30, 2026Sold 6,153 shares at $116.99 of Kymera Therapeutics²
• Jun 30, 2026Sold 7,971 shares at $115.82 of Kymera Therapeutics²
• Jun 30, 2026Sold 51,375 shares at $114.77 of Kymera Therapeutics²
• Jun 30, 2026Sold 4,110 shares at $114.19 of Kymera Therapeutics²
• Jun 30, 2026Sold 1,100 shares at $112.79 of Kymera Therapeutics²
• Jun 30, 2026Sold 1,700 shares at $111.57 of Kymera Therapeutics²
• Jun 30, 2026Sold 1,500 shares at $110.54 of Kymera Therapeutics²
• Jun 30, 2026Exercised options 61,378 shares at $5.33 of Kymera Therapeutics²
• Jun 2, 2026Exercised options 12,653 shares at $2.08 of Kymera Therapeutics³
• May 18, 2026Exercised options 15,000 shares at $2.08 of Kymera Therapeutics⁴
• Mar 4, 2026Sold 447 shares at $86.62 of Kymera Therapeutics⁵
• Mar 4, 2026Sold 1,437 shares at $85.78 of Kymera Therapeutics⁵
• Mar 4, 2026Sold 2,519 shares at $85.04 of Kymera Therapeutics⁵
• Mar 4, 2026Sold 492 shares at $84.00 of Kymera Therapeutics⁵
• Mar 2, 2026Sold 4,113 shares at $89.66 of Kymera Therapeutics⁵
• Mar 2, 2026Sold 1,424 shares at $88.50 of Kymera Therapeutics⁵
• Mar 2, 2026Sold 2,039 shares at $87.75 of Kymera Therapeutics⁵
• Mar 2, 2026Granted 17,650 shares of Kymera Therapeutics⁵
• Sep 17, 2025Sold 79,220 shares at $50.00 of Kymera Therapeutics⁶
• Sep 17, 2025Exercised options 79,220 shares at $2.08 of Kymera Therapeutics⁶
• Mar 31, 2025Exercised options 25,000 shares at $2.08 of Kymera Therapeutics⁷
• Mar 3, 2025Sold 1,281 shares at $31.00 of Kymera Therapeutics⁸
• Mar 3, 2025Sold 5,754 shares at $30.33 of Kymera Therapeutics⁸
• Mar 3, 2025Granted 30,000 shares of Kymera Therapeutics⁸